Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022
02 November 2022 - 7:30AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune
disease, today announced it will report third quarter 2022
financial results and provide a general business overview on
Tuesday, November 8, 2022.
Title: Shattuck Labs Third Quarter 2022
Earnings Conference Call Speakers: Taylor
Schreiber, CEO; Lini Pandite, CMO; Andrew Neill, CFO Date
& Time: Tuesday, November 8, 2022 at 4:30 p.m. ET
Dial-in Details: Toll-Free Dial-In Number:
(888) 440-4368; Toll Dial-In Number: (646) 960-0856; Conference ID:
5023003
To listen to the live webcast, please visit the Investor
Relations page of the Shattuck Labs website here. Participants may
register for the call here. While not required, interested
participants are encouraged to join 10 minutes prior to the start
of the event.
A replay of the webcast will be available following the
conclusion of the live call and will be accessible on the Company’s
website.
About Shattuck Labs, Inc.Shattuck Labs, Inc.
(NASDAQ: STTK) is a clinical-stage biotechnology company pioneering
the development of bi-functional fusion proteins as a new class of
biologic medicine for the treatment of patients with cancer and
autoimmune disease. Compounds derived from Shattuck’s proprietary
Agonist Redirected Checkpoint, ARC®, platform simultaneously
inhibit checkpoint molecules and activate costimulatory molecules
with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L)
program, which is designed to block the CD47 immune checkpoint and
simultaneously agonize the CD40 pathway, is being evaluated in
multiple Phase 1 trials. A second product candidate, SL-279252
(PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid
tumors or lymphomas. Additionally, the company is advancing a
proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is
designed to bridge gamma delta T cells to tumor antigens for the
treatment of patients with cancer. Shattuck has offices in both
Austin, Texas and Durham, North Carolina. For more information,
please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its
website as a means of disclosing material non-public information
and for complying with disclosure obligations under Regulation
FD.
Investor Contact: Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024